全文获取类型
收费全文 | 29190篇 |
免费 | 1193篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 433篇 |
儿科学 | 515篇 |
妇产科学 | 342篇 |
基础医学 | 3916篇 |
口腔科学 | 714篇 |
临床医学 | 1972篇 |
内科学 | 7183篇 |
皮肤病学 | 794篇 |
神经病学 | 1901篇 |
特种医学 | 1296篇 |
外国民族医学 | 1篇 |
外科学 | 4760篇 |
综合类 | 153篇 |
一般理论 | 2篇 |
预防医学 | 742篇 |
眼科学 | 333篇 |
药学 | 2087篇 |
7篇 | |
中国医学 | 83篇 |
肿瘤学 | 3259篇 |
出版年
2023年 | 170篇 |
2022年 | 316篇 |
2021年 | 502篇 |
2020年 | 333篇 |
2019年 | 426篇 |
2018年 | 477篇 |
2017年 | 396篇 |
2016年 | 490篇 |
2015年 | 465篇 |
2014年 | 700篇 |
2013年 | 804篇 |
2012年 | 1281篇 |
2011年 | 1407篇 |
2010年 | 769篇 |
2009年 | 745篇 |
2008年 | 1236篇 |
2007年 | 1443篇 |
2006年 | 1326篇 |
2005年 | 1404篇 |
2004年 | 1337篇 |
2003年 | 1210篇 |
2002年 | 1166篇 |
2001年 | 1060篇 |
2000年 | 982篇 |
1999年 | 930篇 |
1998年 | 339篇 |
1997年 | 252篇 |
1996年 | 271篇 |
1995年 | 215篇 |
1994年 | 181篇 |
1993年 | 205篇 |
1992年 | 645篇 |
1991年 | 556篇 |
1990年 | 543篇 |
1989年 | 543篇 |
1988年 | 518篇 |
1987年 | 490篇 |
1986年 | 465篇 |
1985年 | 428篇 |
1984年 | 316篇 |
1983年 | 260篇 |
1982年 | 162篇 |
1979年 | 246篇 |
1977年 | 186篇 |
1973年 | 177篇 |
1972年 | 186篇 |
1971年 | 190篇 |
1970年 | 172篇 |
1969年 | 186篇 |
1968年 | 170篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Fukunaga Tsugumi Anan Go Hirose Takuo Miyake Yuka Hoshino Kento Endo Akari Tajima Ryo Ito Hiroki Nakayama Shingo Hashimoto Hideaki Ishiyama Katsuya Kimura Tomoyoshi Mori Takefumi 《Clinical and experimental nephrology》2022,26(7):717-723
Clinical and Experimental Nephrology - The number of patients aged ≥ 75 years and who need renal replacement therapy is steadily increasing. The study aimed to determine... 相似文献
102.
103.
Mase Kaori Saito Chie Usui Joichi Arimura Yoshihiro Nitta Kosaku Wada Takashi Makino Hirofumi Muso Eri Hirawa Nobuhito Kobayashi Masaki Yumura Wako Fujimoto Shouichi Nakagawa Naoki Ito Takafumi Yuzawa Yukio Matsuo Seiichi Yamagata Kunihiro 《Clinical and experimental nephrology》2022,26(11):1092-1099
Clinical and Experimental Nephrology - The life prognosis of elderly patients with myeloperoxidase–anti-neutrophil cytoplasmic antibodies-associated vasculitis (MPO-AAV) has been improved by... 相似文献
104.
105.
Yoshihiro Nishida Kunihiro Ikuta Shinji Ito Hiroshi Urakawa Tomohisa Sakai Hiroshi Koike Kan Ito Shiro Imagama 《Cancer science》2021,112(3):1114-1122
The purposes of this study were to re-confirm the usefulness of PET/CT in the differentiation of benignity/malignancy of neurogenic tumors in NF1 patients, and to analyze the natural course of plexiform neurofibroma (pNF) and clarify whether PET/CT is also useful for detecting tumors other than neurogenic tumors. PET/CT was prospectively imaged in 36 NF1 patients. There were 14 malignant peripheral nerve sheath tumors (MPNSTs) in 14 patients, and 54 pNFs in 30 patients. Nine patients had both MPNST and pNF. Maximal standardized uptake value (SUVmax) was significantly higher in MPNST (median 7.6: range 4.1-10.4) (P < .001) compared with that of pNF (median 3.7: range 1.6-9.3). The cut-off value of 5.8 resulted in a sensitivity of 78.6% and specificity of 88.9%. Median age was 29 y, and median maximum tumor diameter was 82 mm in 14 MPNST patients. The 5-y overall survival rate was 46.8%. Three patients with low-grade MPNST were alive without disease at the time of this report. In 9 patients in which pNF and MPNST co-existed, 2 showed a higher SUVmax of pNF than that of MPNST. Natural history analysis of pNF (n = 43) revealed that no factors significantly correlated with increased tumor size. Nine lesions other than neurogenic tumors were detected by PET/CT including 5 thyroid lesions and 3 malignant neoplasms. This study revealed the usefulness and limitation of PET/CT for NF1 patients. In the future, it will be necessary to study how to detect over time the malignant transformation of pNF to MPNST, via an intermediate tumor. 相似文献
106.
Ishitani Ken Isoai Ayako Ito Tetsuya Sugiyama Hiroshi Arakawa Atsushi Yamada Yosuke Onodera Hirokazu Kobayashi Ryosuke Torii Naoko Soneda Noriko Matsuno Yoshihiro Utsugisawa Taiju Kato Michio Hanafusa Norio 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1130-1138
International Journal of Clinical Oncology - Cell-free and concentrated ascites reinfusion therapy (CART) has been suggested to be able to treat malignant ascites more safely and effectively with... 相似文献
107.
Miyake Hideaki Sato Ryo Watanabe Kyohei Matsushita Yuto Watanabe Hiromitsu Motoyama Daisuke Ito Toshiki Sugiyama Takayuki Otsuka Atsushi 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(9):1745-1751
International Journal of Clinical Oncology - Cabazitaxel has played an important role in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC); however, several... 相似文献
108.
Ito K Utsunomiya H Suzuki T Saitou S Akahira J Okamura K Yaegashi N Sasano H 《Molecular and cellular endocrinology》2006,248(1-2):136-140
In situ estrogen metabolism and synthesis have been considered to play a very important role in the development and progression of human endometrial carcinoma. 17Beta-hydroxysteroid dehydrogenases (17-HSDs) are enzymes involved in the formation of active sex steroids, including testosterone, estrone (E1) and estradiol (E2). Estrogens are interchanged by two enzymes, 17-HSD types 1 and 2, type 1 converts E1 to E2, and type 2 does reverse actions. 17-HSD type 5 catalyzes the reduction of androstenedione to testosterone. 17-HSD type 2 expression was decreased through normal endometrium, hyperplasia and carcinoma accordingly. There was a significant inverse correlation between intratumoral E2 concentration and the level of 17-HSD type 2 mRNA in endometrial carcinoma. 17-HSD type 5 expression was significantly increased through normal endometrium, hyperplasia and carcinoma accordingly. These results indicated that 17-HSD types 2 and 5 play an important role in the regulation of in situ estrogen production in endometrial carcinoma. 相似文献
109.
Takano T Saito J Soyama A Ito H Iizuka T Yoshida T Nishikawa T 《Endocrine journal》2006,53(2):209-212
We report a 35-year-old woman with active acromegaly despite pituitary surgery and irradiation who received continuous octreotide LAR treatment for the control of GH excess until discovery of her pregnancy. The patient delivered a healthy boy following an uneventful pregnancy after discontinuing octreotide LAR as soon as possible at the early phase of pregnancy. Despite a substantial maternal-fetal transfer of octreotide, postnatal development was normal at 3 years of age. In almost all previously described cases, octreotide was discontinued after pregnancy was confirmed. No side-effects of mother or fetus have been reported. Octreotide treatment in pregnancy seems to be feasible and safe. Due to the still-limited number of reported cases treated with octreotide LAR, the potential benefits of octreotide LAR treatment should be weighed carefully against its possible risks. 相似文献
110.
Nakazawa S Maoka T Uemura H Ito Y Kanbara H 《Antimicrobial agents and chemotherapy》2002,46(4):958-965
Recrudescences were simulated in vitro with drug treatment to examine how drug-sensitive parasites survive the treatment. Various numbers of cultured parasites were treated with lethal doses of pyrimethamine or mefloquine for various lengths of time. Recrudescences were observed in parasite populations with larger initial numbers of parasites when the treatment duration was prolonged. Equal numbers of parasitized erythrocytes were treated with various concentrations of pyrimethamine or mefloquine. There was no clear linear relationship between the incidence of recrudescence and the drug concentration. Parasites that had recrudesced were continuously allowed to recrudesce in the succeeding recrudescence experiments. Both the duration from the cessation of treatment to the time at which the recrudescent parasitemia level reached 1% and the growth rate of recrudescent parasites were equal among these recrudescences. The recrudescent parasites in these experiments were as sensitive to the drugs as the parasites tested before treatment were. These results suggest that a parasite culture may contain parasites in some phases that are not killed by drug for up to 10 days, which explains the recrudescences that occur even after treatment. 相似文献